In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers
are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical …

Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …

Microglia are the most abundant immune cells in the central nervous system (CNS), where
they interact with neurons and exhibit a wide array of functions in physiological and …

A major challenge in Parkinson's disease is the variability in symptoms and rates of
progression, underpinned by heterogeneity of pathological processes. Biomarkers are …

Parkinson's Disease (PD) is a highly prevalent neurodegenerative disease among older
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …

Parkinson's disease is the second most common neurodegenerative disorder after
Alzheimer's disease and is estimated to affect approximately 1–4% of individuals aged over …

Accumulation of α-synuclein into toxic oligomers or fibrils is implicated in dopaminergic
neurodegeneration in Parkinson's disease. Here we performed a high-throughput, proteome …

Parkinson's disease (PD) is a complex neurodegenerative disorder with no cure in sight.
Clinical challenges of the disease include the inability to make a definitive diagnosis at the …

The role of phagocytosis in the neuroprotective function of microglia has been appreciated
for a long time, but only more recently a dysregulation of this process has been recognized …

The synuclein family includes three neuronal proteins, named α‐synuclein, β‐synuclein, and
γ‐synuclein, that have peculiar structural features. α‐synuclein is largely known for being a …